Neovascular (WET) age-related macular degeneration
Clinical trials for Neovascular (WET) age-related macular degeneration explained in plain language.
Never miss a new study
Get alerted when new Neovascular (WET) age-related macular degeneration trials appear
Sign up with your email to follow new studies for Neovascular (WET) age-related macular degeneration, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a single gene therapy injection hold back wet AMD for years?
Disease control Recruiting nowThis study follows people with wet age-related macular degeneration who received an injection of SKG0106, an experimental gene therapy, in an earlier trial. Researchers will track their eye health, vision, and any side effects for up to 5 years after the injection. The goal is to…
Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Sponsor: Skyline Therapeutics • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
One-Time gene shot could cut eye injections for wet AMD
Disease control Recruiting nowThis study tests a gene therapy called 4D-150 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single injection into the eye can safely reduce the need for regular anti-VEGF shots. About 215 adults aged 50 and old…
Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Phase 1/2 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New eye injection could reduce treatment frequency for wet AMD
Disease control Recruiting nowThis early-stage trial tests a new medicine called EYC-0305, given as an eye injection every 24 weeks, in 30 people aged 50 and older with wet age-related macular degeneration (AMD). The main goal is to check if the treatment is safe and tolerable. Researchers will also measure h…
Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Phase 1/2 • Sponsor: Eyconis INC. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC